CAMBIO DE DISCURSO : LA SECOND-LINE SCLC-ES TRAS EL FIASCO DE LA FASE III LAGOON YA MEJOR NI NOMBRARLA...CAMBIAMOS DISCURSO A MANTENIMIENTO EN FIRTS-LINE Y PASAMOS DEL VIAL DE 4 Mg AI VIAL DE 2 Mg .//. JazzPharma TO WITHDRAW LURBINECTEDIN WITH US_FDA IN SECOND-LINE SCLC-ES...EN ESPAÑA NO SE HAN ENTERADO AÚN...SI NO EXISTIERA IMFORTE...AHORA MISMO PHARMAMAR ESTARÍA ANTE UNA GRAVE SITUACIÓN ... 2 DE OCTUBRE DE 2028 ... ES LA FECHA MÁS TEPMPRANA PARA LA POSIBLE ENTRADA DE GENÉRICOS .
06 febrero 2007
Cáncer ,“el concepto de curación es muy abstracto”. “Cuando dentro de unas décadas se analicen nuestros métodos seguramente pensarán que son inhumano
Josep Baselga , ganador del "PREMIO INICIATIVA BMW 2007” .
05 febrero 2007
Synthesis of IB-01211, a Cyclic Peptide Containing 2,4-Concatenated Thia- and Oxazoles, via Hantzsch Macrocyclization.
2007 Feb 1 .
Synthesis of IB-01211, a Cyclic Peptide Containing 2,4-Concatenated Thia- and Oxazoles, via Hantzsch Macrocyclization.
Hernandez D, Vilar G, Riego E, Canedo LM, Cuevas C, Albericio F, Alvarez M.
Barcelona Science Park Josep Samitier 1-5, E-08028 Barcelona, Spain.
An efficient and versatile convergent synthesis of IB-01211 based on a combination of peptide and heterocyclic chemistry is described. The key step in the synthesis is macrocyclization through intramolecular Hantzsch formation of the thiazole ring. Dehydration of a free primary alcohol to furnish the exocyclic methylidene present in the natural product was applied during the macrocyclization.
Synthesis of IB-01211, a Cyclic Peptide Containing 2,4-Concatenated Thia- and Oxazoles, via Hantzsch Macrocyclization.
Hernandez D, Vilar G, Riego E, Canedo LM, Cuevas C, Albericio F, Alvarez M.
Barcelona Science Park Josep Samitier 1-5, E-08028 Barcelona, Spain.
An efficient and versatile convergent synthesis of IB-01211 based on a combination of peptide and heterocyclic chemistry is described. The key step in the synthesis is macrocyclization through intramolecular Hantzsch formation of the thiazole ring. Dehydration of a free primary alcohol to furnish the exocyclic methylidene present in the natural product was applied during the macrocyclization.
Aplidin Small cell lung cancer and targeted therapies.
2007 Mar 19
Small cell lung cancer and targeted therapies.
Blackhall FH , Shepherd FA
aChristie Hospital NHS Trust, Manchester, UK bPrincess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada.
PURPOSE OF REVIEW: Small cell lung cancer is a chemosensitive malignancy, yet long-term survival remains elusive for the majority of patients. Here, we report on progress in evaluating novel targeted therapies for the treatment of this disease. RECENT FINDINGS: Interferons, matrix metalloproteinase inhibitors, thalidomide, bevacizumab, ZD6474, imatinib, gefitinib, oblimersen and aplidine have all entered clinical trial in patients with small cell lung cancer. Immunotherapy approaches targeting cell surface antigens such as CD-56 (BB10901) and GD3 ganglioside are also being evaluated. Interferons, matrix metalloproteinase inhibitors, imatinib and gefitinib have failed to demonstrate efficacy for this disease. Preliminary data for thalidomide are promising and so results from trials of other antiangiogenics such as bevacizumab and ZD6474 are awaited with interest. SUMMARY: Although the promise of targeted therapy has yet to be realized in patients with small cell lung cancer, the number of agents available for evaluation provides new optimism that progress will be made over the next decades.
Small cell lung cancer and targeted therapies.
Blackhall FH , Shepherd FA
aChristie Hospital NHS Trust, Manchester, UK bPrincess Margaret Hospital and the University of Toronto, Toronto, Ontario, Canada.
PURPOSE OF REVIEW: Small cell lung cancer is a chemosensitive malignancy, yet long-term survival remains elusive for the majority of patients. Here, we report on progress in evaluating novel targeted therapies for the treatment of this disease. RECENT FINDINGS: Interferons, matrix metalloproteinase inhibitors, thalidomide, bevacizumab, ZD6474, imatinib, gefitinib, oblimersen and aplidine have all entered clinical trial in patients with small cell lung cancer. Immunotherapy approaches targeting cell surface antigens such as CD-56 (BB10901) and GD3 ganglioside are also being evaluated. Interferons, matrix metalloproteinase inhibitors, imatinib and gefitinib have failed to demonstrate efficacy for this disease. Preliminary data for thalidomide are promising and so results from trials of other antiangiogenics such as bevacizumab and ZD6474 are awaited with interest. SUMMARY: Although the promise of targeted therapy has yet to be realized in patients with small cell lung cancer, the number of agents available for evaluation provides new optimism that progress will be made over the next decades.
04 febrero 2007
03 febrero 2007
02 febrero 2007
31 enero 2007
30 enero 2007
Tarceva es aprobado por la U.E. para tratar el Cáncer de Pancreas .
La UE aprueba Tarceva de Roche para tratar el cáncer de páncreasLunes 29 de Enero, 2007 9:48 GMT
ZURICH (Reuters) - La Unión Europea (UE) aprobó el medicamento Tarceva de Roche para tratar el cáncer de páncreas, según informó el lunes el laboratorio, una decisión en línea con las recomendaciones previas de autoridades sanitarias europeas.
Roche dijo que la aprobación se basa en datos de un ensayo de Fase III que demostró que el tratamiento con Tarceva mejora significativamente la sobrevida de los pacientes, comparado con los participantes que sólo recibieron quimioterapia.
El mes pasado, la Agencia Europea de Medicamentos había decidido recomendar Tarceva para el tratamiento del cáncer pancreático después de volver a examinar la evidencia, luego de haber rechazado el fármaco como terapia para el cáncer de páncreas avanzado.
28 enero 2007
Yondelis (Trabectedin ) podria usarse en Oncologia ......Como Antinflamatorio .
Ver en la Pagina 41 del PDF :
Dr. Freedman said that new drugs such as, for example, trabectedin need to be carefully examined in relation to CA-125 modulation because they can modulate the inflammatory component. Macrophage function is the most common inflammatory component associated with ovarian cancer in the peritoneum. What is the relationship of the inflammatory component to CA-125? With the new generation of drugs, there is an opportunity to see the contribution of the inflammatory component to biomarker change. The issue of discordance between CA-125 and objective response needs to be addressed.
Dr. Freedman said that new drugs such as, for example, trabectedin need to be carefully examined in relation to CA-125 modulation because they can modulate the inflammatory component. Macrophage function is the most common inflammatory component associated with ovarian cancer in the peritoneum. What is the relationship of the inflammatory component to CA-125? With the new generation of drugs, there is an opportunity to see the contribution of the inflammatory component to biomarker change. The issue of discordance between CA-125 and objective response needs to be addressed.
Suscribirse a:
Entradas (Atom)